Skip to main content
Premium Trial:

Request an Annual Quote

BG Medicine Amends Galectin-3 Test Sales Agreement With Abbott

NEW YORK (GenomeWeb) – BG Medicine said today that it has amended its agreement with Abbott Laboratories for licensing and distributing its galectin-3 test.

The amendment changes product fees Abbott pays to BG Medicine for galectin-3 tests it sells to reference laboratories. In addition, Abbott was to make a payment of $500,000 to BG Medicine by November 30 and will make another $500,000 payment by June 30, 2016, provided certain commercial milestones are met.

BG said it expects that the modified agreement will help expedite the transition of its galectin-3 test from manual to automated platforms. Currently, the company derives the bulk of its revenues from manual testing, but it aims to move to automated testing.

Moving galectin-3 testing to an automated platform has long been a key part of BG Medicine’s commercial strategy. The company expects that such a move would increase uptake of the test by improving throughput and turnaround time and reducing the amount of labor involved in running it.

In addition to Abbott, the company has partnered with Alere, Siemens, and BioMérieux on developing automated versions of the test.

The amendments to the Abbott agreement cover only sales of the galectin-3 test to reference labs. Product fees will remain the same for sales to other customer segments.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.